Skip to content
Recall Observatory FDA recall evidence

Device product

BD BBL Sensi Disc Ceftazidime- 30 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231632¿and 231633¿

Z-1023-2024

January 08, 2024

Class II

Product summary

Firm
Becton Dickinson & Co.
Event
Event 93789
Status
Ongoing
Classification
Class II
Quantity
2,363,168 total units
Official record key
device-enforcement:Z-1023-2024

Official wording

Reason: There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.

Code information: Catalog No. 231632¿ UDI-DI 00382902316329 Lots 2004587 2028883 2119589 2146527 2242568 2301371 3118111 3181037; Catalog No. 231633¿ UDI-DI 30382902316337 Lots 2242568 2301371 3062286 3118111 3181037 3223389 3290192 2004587 2028232 2028883 2028894 2056528 2119589 2146527

Distribution pattern: Domestic distribution nationwide. International distribution worldwide.

Derived failure modes

  • Unknown

    reason.no_named_rule · v1.0.0

    There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.

Field note

Send feedback

We'll only use this to respond to your feedback.